4A5.F Fagron NV

Healthcare Pharmaceuticals Frankfurt Exchange
24.25 EUR
Close of Nov 11, 2026
19.60 25.15
Market cap
EUR 1.78B
P/E
18.9x
P/B
3.05x
ROE
16.5%
Dividend yield
1.46%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4A5.F undervalued?

Graham number
Price24.25
Graham value15.14
Premium60.2%

4A5.F trades 60.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fagron NV fundamental analysis

No fundamental analysis for Fagron NV yet.

Fagron NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex …

Full company profile